Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.02 - $7.48 $6,834 - $50,116
6,700 Added 22.33%
36,700 $43,000
Q3 2022

Nov 14, 2022

BUY
$6.04 - $9.66 $181,200 - $289,800
30,000 New
30,000 $226,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Annandale Capital, LLC Portfolio

Follow Annandale Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Annandale Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Annandale Capital, LLC with notifications on news.